Hormonal
Deletion of the endocannabinoid-synthesizing enzyme NAPE-PLD specifically in adipose tissue causes obesity, glucose intolerance, and insulin resistance in mice, primarily through impaired adipose browning and altered gut microbiota composition.
This research suggests that the health of your fat tissue is not passive. If the enzymes that produce certain signaling lipids (endocannabinoids) in your fat cells are disrupted, it can trigger a cascade leading to obesity and insulin resistance, partly by changing your gut bacteria. While this is a genetic mouse model, it highlights that metabolic health involves complex communication between fat, gut, and brain, not just food intake.
We found in this study that Napepld deletion in adipose tissue leads to development of obesity, impairment of glucose and lipid homeostasis along with altered adipose tissue metabolism and changes in gut microbiota composition.
Why this rating
High-quality mechanistic evidence using conditional knockout mice, germ-free transfers, and multiple metabolic assays, though limited to murine models.
Source
Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota
Lucie Geurts et al. · Nature Communications · 2015
DOI 10.1038/ncomms7495
More from this paper
- Adipose tissue NAPE-PLD is essential for the browning process of white adipose tissue; its deletion impairs cold-induced thermogenesis and reduces the expression of browning markers like Ucp1 and Ppargc1a.Good
- The metabolic phenotype caused by adipose NAPE-PLD deletion is mediated by changes in gut microbiota composition, as evidenced by the partial transfer of the obese and insulin-resistant phenotype to germ-free mice via fecal microbiota transplantation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →